

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED

東瑞製藥(控股)有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2348)

GRANT OF SHARE OPTIONS

This announcement is made pursuant to Rule 17.06A of the Rules (“Listing Rules”) governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Stock Exchange”).

The board of directors (the “Board”) of Dawnrays Pharmaceutical (Holdings) Limited (the “Company”) hereby announces that on 25 September 2014, 2,700,000 share options (the “Share Options” and each a “Share Option”) were granted to subscribe for a total of 2,700,000 new ordinary shares of HK\$0.1 each (each a “Share”) in the share capital of the Company to the chief executive officer of the Company, Ms. Huang Dongmei (the “Grantee”), subject to acceptance of the Grantee, under the Company’s share option scheme which was adopted and became effective on 21 June 2013. Details of the Share Options are set out as follows:

Date of grant	: 25 September 2014
Exercise price of the Share Options granted	: HK\$7.37 per Share, which represents the highest of (i) the closing price of HK\$7.37 per Share on the date of grant of the Share Options, i.e. 25 September 2014; (ii) the average closing price of HK\$6.862 per Share as stated in the daily quotation sheets issued by the Stock Exchange for the five business days immediately preceding the date of grant.

Number of Share Options granted : 2,700,000

Validity period of the Share Options : From 25 September 2014 to 24 September 2024.
The Share Options are exercisable for a period of nine years commencing on the first anniversary date of the date of grant (i.e. 25 September 2015). The maximum number of Share Options that can be exercised during each anniversary year from 25 September 2015 to 24 September 2024 is 300,000 Share Options together with any unexercised Share Options carried forward from the previous anniversary year(s).

Closing price of the Share on the date of grant : HK\$7.37 per Share

In accordance with Rule 17.04(1) of the Listing Rules, the grant of Share Options to the chief executive officer of the Company, Ms. Huang Dongmei, had been approved by the Independent Non-executive Directors of the Company.

By Order of the Board
Dawnrays Pharmaceutical (Holdings) Limited
Li Kei Ling
Chairman

Hong Kong, 25 September 2014

As at the date of this announcement, the Board of the Company comprises three executive directors, namely Ms. Li Kei Ling, Mr. Hung Yung Lai and Mr. Li Tung Ming; one non-executive director, namely Mr. Leung Hong Man; three independent non-executive directors, namely Mr. Pan Xue Tian, Mr. Choi Tat Ying Jacky and Mr. Lo Tung Sing Tony.

** For identification purpose only*